Otsuka, Lundbeck Win Approval for Monthly Abilify Shot

Otsuka Holdings Co. and H. Lundbeck A/S won approval from U.S. regulators to market a new formulation of the mood-stabilizing drug Abilify as a once-monthly injection to treat schizophrenia.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.